argenx opened a tender offer this morning to acquire Forte Biosciences for $275 million or more, extending the Dutch immunology group's reach into rare inflammatory disorders. The all-cash bid values Forte at a premium to its recent trading range and gives argenx control over FB-102, a Phase 2 candidate for hidradenitis suppurativa and atopic dermatitis. Tender closes mid-second quarter unless extended.

Forte has been capital-constrained since a 2023 restructuring that left clinical programs underfunded and burn rate elevated. The company trades on Nasdaq with a market cap that hovered near $200 million through early 2025, making the premium modest but sufficient to clear board approval. argenx now controls the decision timeline through standard tender mechanics—twenty business days unless shareholder resistance materializes, which Delaware counsel rates as unlikely given Forte's balance sheet position.

The acquisition matters because argenx is no longer a single-product story. VYVGART reached $2.1 billion in trailing twelve-month sales by fourth quarter 2024, establishing the FcRn antagonist platform as a proven commercial engine in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Management has signaled intent to diversify beyond FcRn, and Forte's IL-17 targeting approach addresses large dermatology markets where efficacy benchmarks are well understood. Hidradenitis suppurativa alone represents a $3 billion addressable market with limited biologic penetration, and FB-102's Phase 2 data showed sustained lesion reduction without the dose-limiting toxicities that sank earlier IL-17 inhibitors. argenx gains a de-risked asset that pairs with existing commercial infrastructure in immunology, shortening time to revenue contribution if Phase 3 reads cleanly.

The deal also removes a competitor for scarce dermatology-focused investigators and key opinion leaders, a secondary benefit that accelerates argenx's clinical network consolidation in inflammation. Forte's research team in San Diego will likely integrate into argenx's California operations, where the company already maintains a regulatory and clinical footprint post-VYVGART launch. The tender structure avoids drawn-out proxy fights and keeps integration on a second-quarter timeline, assuming no Department of Justice review triggers, which antitrust counsel rates as minimal given non-overlapping mechanisms.

Operators should watch Forte's shareholder acceptance rate by mid-April, as any resistance below 90 percent forces argenx into a longer merger-of-equals process that delays integration by two quarters. Phase 3 trial design for FB-102 will surface by third quarter 2025 if the tender clears, with topline data expected in 2027. Competitors including AbbVie and Novartis will recalibrate dermatology positioning, particularly if argenx signals intent to combine VYVGART's FcRn platform with IL-17 inhibition in a dual-mechanism strategy.

The premium paid here is not the story. The story is argenx moving from platform validation to portfolio assembly while VYVGART cash flow remains robust and cost of capital stays favorable.